Engineering synthetic vaccines using cues from natural immunity.

Vaccines aim to protect against or treat diseases through manipulation of the immune response, promoting either immunity or tolerance. In the former case, vaccines generate antibodies and T cells poised to protect against future pathogen encounter or attack diseased cells such as tumours; in the latter case, which is far less developed, vaccines block pathogenic autoreactive T cells and autoantibodies that target self tissue. Enormous challenges remain, however, as a consequence of our incomplete understanding of human immunity. A rapidly growing field of research is the design of vaccines based on synthetic materials to target organs, tissues, cells or intracellular compartments; to co-deliver immunomodulatory signals that control the quality of the immune response; or to act directly as immune regulators. There exists great potential for well-defined materials to further our understanding of immunity. Here we describe recent advances in the design of synthetic materials to direct immune responses, highlighting successes and challenges in prophylactic, therapeutic and tolerance-inducing vaccines.

[1]  Dan Peer,et al.  Nanoparticle hydrophobicity dictates immune response. , 2012, Journal of the American Chemical Society.

[2]  R. Langer,et al.  A single-step immunization by sustained antigen release. , 1979, Journal of immunological methods.

[3]  K. Leong,et al.  Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. , 2012, Nature materials.

[4]  P. Cresswell,et al.  Enhanced and prolonged cross‐presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles , 2006, Immunology.

[5]  D. Irvine,et al.  Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction , 2012, Proceedings of the National Academy of Sciences.

[6]  I. M. Belyakov,et al.  Large intestine-targeted nanoparticle-releasing oral vaccine to control genitorectal viral infection , 2012, Nature Medicine.

[7]  John Steel,et al.  Programming the magnitude and persistence of antibody responses with innate immunity , 2010, Nature.

[8]  D. Irvine,et al.  In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles , 2011, Proceedings of the National Academy of Sciences.

[9]  T. Kündig,et al.  Antigen kinetics determines immune reactivity , 2008, Proceedings of the National Academy of Sciences.

[10]  T. Wisniewski,et al.  Immunomodulation for prion and prion-related diseases , 2010, Expert review of vaccines.

[11]  L. Zender,et al.  T-helper-1-cell cytokines drive cancer into senescence , 2013, Nature.

[12]  P. Kozlowski,et al.  Mucosal vaccines: the promise and the challenge , 2006, Nature Reviews Immunology.

[13]  C. Coban,et al.  DNA released from dying host cells mediates aluminum adjuvant activity , 2011, Nature Medicine.

[14]  C. Klebanoff,et al.  Therapeutic cancer vaccines: are we there yet? , 2011, Immunological reviews.

[15]  Samuel K. Lai,et al.  Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses , 2009, Proceedings of the National Academy of Sciences.

[16]  J. Mcghee,et al.  Novel vaccine development strategies for inducing mucosal immunity , 2012, Expert review of vaccines.

[17]  Justin Hanes,et al.  Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus , 2007, Proceedings of the National Academy of Sciences.

[18]  Pau Serra,et al.  Reversal of autoimmunity by boosting memory-like autoregulatory T cells. , 2010, Immunity.

[19]  J. Hubbell,et al.  Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. , 2012, Biomaterials.

[20]  J. Hubbell,et al.  Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination , 2011, Proceedings of the National Academy of Sciences.

[21]  R. Locksley,et al.  The regulation of immunity to Leishmania major. , 1995, Annual review of immunology.

[22]  David J Mooney,et al.  In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice , 2009, Science Translational Medicine.

[23]  Roger Le Grand,et al.  Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Francesco Stellacci,et al.  Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. , 2008, Nature materials.

[25]  Scott N. Mueller,et al.  High antigen levels are the cause of T cell exhaustion during chronic viral infection , 2009, Proceedings of the National Academy of Sciences.

[26]  Hans P. Merkle,et al.  Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres : importance of polymer degradation and antigen release for immune response , 1996 .

[27]  Yen Cu,et al.  In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[28]  J. Villadangos,et al.  The cell biology of cross‐presentation and the role of dendritic cell subsets , 2008, Immunology and cell biology.

[29]  N. Haigwood,et al.  The Use of Nonhuman Primate Models in HIV Vaccine Development , 2008, PLoS medicine.

[30]  J. Hubbell,et al.  Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. , 2011, Vaccine.

[31]  L. Harrison Vaccination against self to prevent autoimmune disease: the type 1 diabetes model , 2008, Immunology and cell biology.

[32]  R. Zinkernagel,et al.  The influence of antigen organization on B cell responsiveness. , 1993, Science.

[33]  Karan Sharma,et al.  Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. , 2008, Immunity.

[34]  C. Hung,et al.  HPV and Therapeutic Vaccines: Where are We in 2010? , 2010 .

[35]  J. Remon,et al.  Facile two-step synthesis of porous antigen-loaded degradable polyelectrolyte microspheres. , 2010, Angewandte Chemie.

[36]  S. Dow,et al.  Efficient Immunization and Cross-Priming by Vaccine Adjuvants Containing TLR3 or TLR9 Agonists Complexed to Cationic Liposomes1 , 2006, The Journal of Immunology.

[37]  Daniel G. Anderson,et al.  pH-Triggered Microparticles for Peptide Vaccination , 2004, The Journal of Immunology.

[38]  R. Valenta,et al.  Vaccines for allergy , 2012, Current opinion in immunology.

[39]  F. Caruso,et al.  Enzyme encapsulation in layer-by-layer engineered polymer multilayer capsules. , 2000 .

[40]  Jangwook P. Jung,et al.  A self-assembling peptide acting as an immune adjuvant , 2009, Proceedings of the National Academy of Sciences.

[41]  Ronald N Germain,et al.  Vaccines and the future of human immunology. , 2010, Immunity.

[42]  F. Caruso,et al.  Binding, Internalization, and Antigen Presentation of Vaccine‐Loaded Nanoengineered Capsules in Blood , 2008 .

[43]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[44]  C. Foged,et al.  License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[45]  E. Lavelle,et al.  The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants , 2010, European journal of immunology.

[46]  Polly Matzinger,et al.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.

[47]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[48]  Melody A Swartz,et al.  Autologous morphogen gradients by subtle interstitial flow and matrix interactions. , 2006, Biophysical journal.

[49]  Benjamin C. Tang,et al.  Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier , 2009, Proceedings of the National Academy of Sciences.

[50]  Michael Sela,et al.  Therapeutic vaccines in autoimmunity , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[51]  M. Bevan,et al.  Constitutive versus Activation-dependent Cross-Presentation of Immune Complexes by CD8+ and CD8− Dendritic Cells In Vivo , 2002, The Journal of experimental medicine.

[52]  Demetri Psaltis,et al.  Precision intracellular delivery based on optofluidic polymersome rupture. , 2012, ACS nano.

[53]  R. Medzhitov,et al.  Toll-dependent selection of microbial antigens for presentation by dendritic cells , 2006, Nature.

[54]  Mary E Napier,et al.  PRINT: a novel platform toward shape and size specific nanoparticle theranostics. , 2011, Accounts of chemical research.

[55]  James E. Evans,et al.  Molecular identification of a danger signal that alerts the immune system to dying cells , 2003, Nature.

[56]  N. Van Rooijen,et al.  Simultaneous Targeting of Toll- and Nod-Like Receptors Induces Effective Tumor-Specific Immune Responses , 2012, Science Translational Medicine.

[57]  Wah Chiu,et al.  Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.

[58]  J. Ulmer,et al.  Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles , 2003, Journal of Virology.

[59]  Shuzhao Li,et al.  Systems vaccinology: learning to compute the behavior of vaccine induced immunity , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.

[60]  C. Liu,et al.  Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion , 2013, Nature Medicine.

[61]  Francisco J. Quintana,et al.  Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis , 2012, Proceedings of the National Academy of Sciences.

[62]  R. Germain,et al.  Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis , 1995, The Journal of experimental medicine.

[63]  Bali Pulendran,et al.  The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid). , 2009, Biomaterials.

[64]  J. DeSimone,et al.  Development of a nanoparticle-based influenza vaccine using the PRINT technology. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[65]  Jie Li,et al.  Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1 , 2004, The Journal of Immunology.

[66]  J. Hubbell,et al.  Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. , 2010, Vaccine.

[67]  B. Walker,et al.  Immunology and the elusive AIDS vaccine , 2010, Nature.

[68]  Jean Paul Remon,et al.  Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection. , 2012, ACS nano.

[69]  Benjamin C. Tang,et al.  Mucus-Penetrating Nanoparticles for Vaginal Drug Delivery Protect Against Herpes Simplex Virus , 2012, Science Translational Medicine.

[70]  J. Hubbell,et al.  Peripherally Administered Nanoparticles Target Monocytic Myeloid Cells, Secondary Lymphoid Organs and Tumors in Mice , 2013, PloS one.

[71]  Ryan F. Donnelly,et al.  Skin Dendritic Cell Targeting via Microneedle Arrays Laden with Antigen-Encapsulated Poly-d,l-lactide-co-Glycolide Nanoparticles Induces Efficient Antitumor and Antiviral Immune Responses , 2013, ACS nano.

[72]  W. J. Meek,et al.  THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY. , 1938, Science.

[73]  M. Willart,et al.  Surface-engineered polyelectrolyte multilayer capsules: synthetic vaccines mimicking microbial structure and function. , 2012, Angewandte Chemie.

[74]  R. Valenta,et al.  From allergen genes to allergy vaccines. , 2010, Annual review of immunology.

[75]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[76]  J. Stockman,et al.  Dissolving polymer microneedle patches for influenza vaccination , 2012 .

[77]  S. Amigorena,et al.  Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ–resident dendritic cells , 2013, The Journal of experimental medicine.

[78]  Darrell J Irvine,et al.  Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. , 2007, Nano letters.

[79]  M. Jenkins,et al.  The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. , 2007, Immunity.

[80]  Aaron J. Martin,et al.  Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis , 2012, Nature Biotechnology.

[81]  Jun Jiao,et al.  Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response , 2011, Nature nanotechnology.

[82]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[83]  L. Holm,et al.  The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[84]  A. Gettie,et al.  Protection against vaginal SIV transmission with microencapsulated vaccine. , 1993, Science.

[85]  K. Rock,et al.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization , 2008, Nature Immunology.

[86]  M. Kovacsovics-Bankowski,et al.  A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules , 1995, Science.

[87]  Naveen Palath,et al.  Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses. , 2013, Vaccine.

[88]  Richard A Flavell,et al.  Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. , 2009, Vaccine.

[89]  Michael S Roberts,et al.  Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. , 2010, Small.

[90]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[91]  R. Gupta,et al.  In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. , 1996, Vaccine.

[92]  Jamal S. Lewis,et al.  Microparticle surface modifications targeting dendritic cells for non-activating applications. , 2012, Biomaterials.

[93]  E. Wherry,et al.  Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment , 2003, Journal of Virology.

[94]  H. Lindén,et al.  The European Federation for Pharmaceutical Sciences , 2003 .

[95]  I. M. Belyakov,et al.  Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. , 2010, The Journal of clinical investigation.

[96]  Thomas Krucker,et al.  Nonviral delivery of self-amplifying RNA vaccines , 2012, Proceedings of the National Academy of Sciences.

[97]  E. Dolgin The inverse of immunity , 2010, Nature Medicine.

[98]  Li Tang,et al.  Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates. , 2012, ACS nano.

[99]  M. Galinski,et al.  The relevance of non-human primate and rodent malaria models for humans , 2011, Malaria Journal.

[100]  L. Old,et al.  Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient , 2008, Cancer Immunology, Immunotherapy.

[101]  Christopher B Wilson,et al.  A decade of vaccines: Integrating immunology and vaccinology for rational vaccine design. , 2010, Immunity.

[102]  S. Schwendeman,et al.  Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide) , 2000, Nature Biotechnology.

[103]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[104]  Manmohan J. Singh,et al.  Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[105]  J. Hubbell,et al.  PEG-b-PPS-b-PEI micelles and PEG-b-PPS/PEG-b-PPS-b-PEI mixed micelles as non-viral vectors for plasmid DNA: tumor immunotoxicity in B16F10 melanoma. , 2011, Biomaterials.

[106]  K. Wittrup,et al.  Antigen Release Kinetics in the Phagosome Are Critical to Cross-Presentation Efficiency1 , 2008, The Journal of Immunology.

[107]  M. Swartz,et al.  VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. , 2012, Cell reports.

[108]  Ping Zhang,et al.  Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity , 2011, Nature Medicine.

[109]  C. Figdor,et al.  Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. , 2011, Blood.

[110]  H. Kiyono,et al.  Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. , 2010, Nature materials.

[111]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[112]  Jean M. J. Fréchet,et al.  A macromolecular delivery vehicle for protein-based vaccines: Acid-degradable protein-loaded microgels , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[113]  Ashutosh Kumar Singh,et al.  An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[114]  J. Ravetch,et al.  Antibody‐mediated modulation of immune responses , 2010, Immunological reviews.

[115]  P. Marrack,et al.  Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.

[116]  Paula T Hammond,et al.  Polymer multilayer tattooing for enhanced DNA vaccination. , 2013, Nature materials.

[117]  J. Hubbell,et al.  Engineering complement activation on polypropylene sulfide vaccine nanoparticles. , 2011, Biomaterials.

[118]  Jeffrey A Hubbell,et al.  Engineering Approaches to Immunotherapy , 2012, Science Translational Medicine.

[119]  J. Tschopp,et al.  Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome , 2009, Proceedings of the National Academy of Sciences.

[120]  Carl A. Batt,et al.  Single-Walled Carbon Nanotubes Deliver Peptide Antigen into Dendritic Cells and Enhance IgG Responses to Tumor-Associated Antigens , 2011, ACS nano.

[121]  H. M. Nielsen,et al.  Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[122]  S. Broderick,et al.  Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. , 2011, Biomaterials.

[123]  V. Appay,et al.  CD8+ T cell efficacy in vaccination and disease , 2008, Nature Medicine.

[124]  Michael S. Goldberg,et al.  Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery , 2012, Proceedings of the National Academy of Sciences.

[125]  A. Rudensky,et al.  Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. , 2003, Immunity.

[126]  David J. Mooney,et al.  Infection-Mimicking Materials to Program Dendritic Cells In Situ , 2008, Nature materials.

[127]  D. Irvine,et al.  Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[128]  S. Plotkin,et al.  Vaccines: past, present and future , 2005, Nature Medicine.

[129]  James Mitchell Crow,et al.  HPV: The global burden , 2012, Nature.

[130]  A. Aderem,et al.  A 2020 vision for vaccines against HIV, tuberculosis and malaria , 2011, Nature.

[131]  Shizuo Akira,et al.  The roles of TLRs, RLRs and NLRs in pathogen recognition. , 2009, International immunology.

[132]  D. Irvine,et al.  In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. , 2011, Molecular pharmaceutics.